| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2022―Apr―26 |
The safe use of iInflammatory bBowel dDisease therapies during the COVID-19 pandemic |
Chethana Kamath, Erica Brenner |
| 2 |
[GO] |
2022―Apr―01 |
COVID-19 therapy, from lung disease to systemic disorder. |
Isabella Zanella |
| 3 |
[GO] |
2022―Feb―04 |
Therapeutics for COVID-19 and post COVID-19 complications: An update |
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta |
| 4 |
[GO] |
2021―Dez―04 |
Strategies for drug repurposing against coronavirus targets |
Poppy O. Smith, Peiqin Jin, Khondaker Miraz Rahman |
| 5 |
[GO] |
2021―Nov―03 |
Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19 |
Amani E. Khalifa, Asser I. Ghoneim |
| 6 |
[GO] |
2021―Okt―22 |
Potential inhibitors of SARS-CoV-2 (COVID 19) spike protein of the delta and delta plus variant: In silico studies of medicinal plants of North-East India |
Peter Solo, M. Arockia doss |
| 7 |
[GO] |
2021―Okt―12 |
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response |
William Migo, Marko Boskovic, Robert Likic |
| 8 |
[GO] |
2021―Okt―12 |
An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19 |
G.S.N. Koteswara Rao, Buduru Gowthami, N. Raghavendra Naveen, Pavan Kumar Samudrala |
| 9 |
[GO] |
2021―Okt―06 |
Can the application of graphene oxide contribute to the fight against COVID-19? Antiviral activity, diagnosis and prevention |
Asmaa Rhazouani, Khalid Aziz, Halima Gamrani, Lhoucine Gebrati, Md Sahab Uddin, Aziz Faissal |
| 10 |
[GO] |
2021―Sep―27 |
Host directed therapies: COVID-19 and beyond |
Devavrat Tripathi, Megha Sodani, Pramod Kumar Gupta, Savita Kulkarni |
| 11 |
[GO] |
2021―Sep―16 |
Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients |
Antonio Vitiello, Francesco Ferrara |
| 12 |
[GO] |
2021―Sep―14 |
Recent progress in the development of potential drugs against SARS-CoV-2 |
Jianmin Chen, Fayaz Ali, Imran Khan, Yi Zhun Zhu |
| 13 |
[GO] |
2021―Sep―11 |
Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19 |
Amgad M. Rabie |
| 14 |
[GO] |
2021―Aug―27 |
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19? |
Alexander Hooftman, Luke A.J. O'Neill |
| 15 |
[GO] |
2021―Jul―28 |
Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2 |
Kartikay Prasad, Vijay Kumar |
| 16 |
[GO] |
2021―Jun―05 |
Pathophysiology and possible treatments for olfactory-gustatory disorders in patients affected by COVID-19 |
Francisca Idalina Neta, Amélia Carolina Lopes Fernandes, Adson José Martins Vale, Francisco Irochima Pinheiro, Ricardo Ney Cobucci, Eduardo Pereira de Azevedo, Fausto Pierdoná Guzen |
| 17 |
[GO] |
2021―Jun―05 |
Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/ 3CLpro: molecular docking and simulation studies of three pertinent medicinal plant natural components |
Devvret Verma, Debasis Mitra, Manish Paul, Priya Chaudhary, Anshul Kamboj, Hrudayanath Thatoi, et al. (+6) Pracheta Janmeda, Divya Jain, P. Panneerselvam, Rakesh Shrivastav, Kumud Pant, Pradeep K. Das Mohapatra |
| 18 |
[GO] |
2021―Mai―14 |
Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2 |
Nilesh Gajanan Bajad, Swetha Rayala, Gopichand Gutti, Anjali Sharma, Meenakshi Singh, Ashok Kumar, Sushil Kumar Singh |
| 19 |
[GO] |
2021―Mai―09 |
Hypoxia may be a determinative factor in COVID-19 progression |
Pawel Grieb, Maciej Swiatkiewicz, Katarzyna Prus, Konrad Rejdak |
| 20 |
[GO] |
2021―Apr―30 |
A Research Update: Significance of Cytokine Storm and Diaphragm in COVID-19 |
Ashwani Mittal, Anita Dua, Sanjeev Gupta, Elisha Injeti |
